CZR three-lens brief
Evidence-based stock research on CZR. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Trading at 90% of its 52-week range — near the top of the band.
- Trading at 90% of its 52-week range — near the top of the band.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Debt-to-equity of 723% — balance-sheet-heavy.
- Earnings scheduled 2026-07-28.
CZR closed at $29.89 (+0.42%) as of 2026-07-10. Market cap: $6.09B. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.. Concerns: trading at 90% of its 52-week range — near the top of the band.; currently unprofitable on a trailing basis — no P/E multiple available.. Last quarter: Revenue $2.87B, net income -$98.00M, free cash flow $752.63M. Watching for: 2026-07-28 earnings release (17 days out).
Why three lenses on CZR, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CZRacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CZR" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CZR brief"></iframe>